Laryngeal preservation in ENT oncology. Retrospective series of 246 patients managed in the Caen University Hospital and François Baclesse Cancer Care Center between 1998 and 2008

European Annals of Otorhinolaryngology, Head and Neck Diseases

Volumn 132, Issue 3, 2015, Pages 129-134

  Cuny, F ^a,b   Meunier, A ^a   Heutte, N ^b,c   Rame, J P ^a   De Raucourt, D ^a   Babin, E ^a,b   Blanchard, D ^a,b  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers'   (France)

^c UNIVERSITÉ DE CAEN   (France)

Author keywords

BMI; Chemotherapy; Laryngeal cancer; Laryngeal preservation; Laryngeal surgery; Radiation therapy

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANNULA; CERVICAL LYMPHADENOPATHY; CONSERVATIVE TREATMENT; CONSULTATION; DIARRHEA; DYSPHAGIA; DYSPHONIA; DYSPNEA; FEMALE; HEALTH STATUS; HEMOPTYSIS; HUMAN; HYPOPHARYNX CANCER; INDUCTION CHEMOTHERAPY; LARNYNX PRESERVATION; LARYNGECTOMY; LARYNX; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; NECK DISSECTION; NEUTROPENIA; NUTRITIONAL STATUS; ORGAN PRESERVATION; OTALGIA; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REFERRED PAIN; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL TIME; TIME TO TREATMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; VOMITING; WORLD HEALTH ORGANIZATION; ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; ADVERSE EFFECTS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; DRINKING BEHAVIOR; FRANCE; KAPLAN MEIER METHOD; LARYNGEAL NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROCEDURES; SMOKING; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FRANCE; HUMANS; KAPLAN-MEIER ESTIMATE; LARYNGEAL NEOPLASMS; LARYNGECTOMY; MALE; MIDDLE AGED; ORGAN SPARING TREATMENTS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; TREATMENT OUTCOME;

EID: 84930929704     PISSN: 18797296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anorl.2015.03.007     Document Type: Article

References (25)

1. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriformsinus cancer: Preliminary results of a European Organization for Research andTreatment of Cancer phase III trial. J Natl Cancer Inst 1996;88(13):890-9.
2. Janot F, Rhein B, Koka VN, et al. Laryngeal preservation with inductionchemotherapy. Experience of two GETTEC centers, between 1985 and 1995.Ann Otolaryngol Chir CervicoFac 2002;119(1):12-20.
3. Decker DA, Drelichman A, Jacobs J, et al. Adjuvant chemotherapy withcis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil instage III and IV squamous cell carcinoma of the head and neck. Cancer1983;51(8):1353-5.
4. Lefebvre JL, Coche-Dequeánt B, Degardin M, et al. Treatment of laryngeal can-cer: The permanent challenge. Expert Rev Anticancer Ther 2004;4(5):913-20.
5. Arzul Ethèse Préservation laryngeé par association de chimiothérpaie etradiothérapie. Expérience lilloise sur 163 cancers pharyngo-laryngés traitésde 1985 à 2005. Lille: Université de droit et de la santé-Lille 2; 2007.
6. Gamby R [thèse] Préservation laryngeé dans les carcinomes épidermoïdes dularynx et de l'hypopharynx. Résultats carcinologiques et fonctionnels de 103cas pris en charge au CHU de Rennes. Université Rennes 1; 2008.
7. Spaulding MB, Fischer SG, Wolf GT, et al. Tumor response, toxicity, and survivalafter neoadjuvant organ-preserving chemotherapy for advanced laryngeal car-cinoma. J Clin Oncol 1994;12(8):1592-9.
8. Bourhis J, Lefebvre JL, Temam S, et al. Larynx preservation: Non-surgicalapproaches. Cancer Radiother 2004;8(Suppl. 1):S24-8.
9. Nguyen-Tan PF, Le QT, Quivey JM, et al. Treatment results and prognostic fac-tors of advanced T3-4 laryngeal carcinoma: The University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience. Int J RadiatOncol Biol Phys 2001;50(5):1172-80.
10. Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic fac-tors and survival in locoregionally advanced head and neck cancer treated withconcomitant chemoradiotherapy: A 9-year, 337-patient, multi-institutionalexperience. Ann Oncol 2004;15(8):1179-86.
11. Parr CL, Batty GD, Lam TH, et al. Body mass index and cancer mortality in theAsia-Pacific cohort studies collaboration: Pooled analyses of 424, 519 partici-pants. Lancet Oncol 2010;11(8):741-52.
12. Park SL, Lee Y-CA, Marron M, et al. The association between change in body massindex and upper aerodigestive tract cancers in the ARCAGE project: Multicentercase-control study. J Int Cancer 2011;128(6):1449-61.
13. Lubin JH, Gaudet MM, Olshan AF, et al. Body mass index, cigarette smok-ing, and alcohol consumption and cancers of the oral cavity, pharynx, andlarynx: Modeling odds ratios in pooled case-control data. Am J Epidemiol2010;171(12):1250-61.
14. Marandas P, Marandas N. Épidémiologie des voies aérodigestives supérieures.Traité d'ORL. Flammarion: 481-91; 2008.
15. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induc-tion chemotherapy plus radiation compared with surgery plus radiationin patients with advanced laryngeal cancer. N Engl J Med 1991;324(24):1685-90.
16. Zelefsky MJ, Kraus DH, Pfister DG, et al. Combined chemotherapy andradiotherapy versus surgery and postoperative radiotherapy for advancedhypopharyngeal cancer. Head Neck 1996;18(5):405-11.
17. Richard JM, Sancho-Garnier H, Pessey JJ, et al. Randomized trial of inductionchemotherapy in larynx carcinoma. Oral Oncol 1998;34(3):224-8.
18. Pignon J-P, le Maître A, Bourhis J. Meta-analyses of chemotherapy in head andneck cancer (MACH-NC): An update. Int J Radiat Oncol Biol Phys 2007;69(2Suppl.):S112-4.
19. Lefebvre J. Sequantial chemoradiotheraoy (SCRT) for larynx preservation (LP):results of the randomized phase II TREMPLIN study. J Clin Oncol 2009;27(15s)[Suppl.; abstr 6010].
20. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: Acomparison of three non-surgical treatment strategies to preserve the larynx inpatients with locally advanced larynx cancer. J Clin Oncol 2013;31(7):845-52.
21. Francis E, Matar N, Khoueir N, et al. T4a laryngeal cancer survival:retrospective institutional analysis and systematic review. Laryngoscope2014;124(7):1618-23.
22. Staton J, Robbins KT, Newman L, et al. Factors predictive of poor functional out-come after chemoradiation for advanced laryngeal cancer. Otolaryngol HeadNeck Surg 2002;127(1):43-7.
23. Babin E, Sigston E, Hitier M, et al. Quality of life in head and neck cancerspatients: Predictive factors, functional and psychosocial outcome. Eur ArchOtorhinolaryngol 2008;265(3):265-70.
24. Babin E, Grandazzi G. Cooperation between medicine and sociology in headand neck oncology. Otolaryngol Head Neck Surg 2014;150(5):712-5.
25. Vickery LE, Latchford G, Hewison J, et al. The impact of head and neck cancerand facial disfigurement on the quality of life of patients and their partners.Head Neck 2003;25(4):289-96.